Portfolio company DJS Antibodies was acquired by AbbVie.
DJS Antibodies focuses on creating the next generation of antibody therapeutics using their HEPTAD platform for antibody discovery, aimed at improving the lives of patients with chronic inflammatory diseases
DJS Antibodies focuses on creating the next generation of antibody therapeutics using their HEPTAD platform for antibody discovery, aimed at improving the lives of patients with chronic inflammatory diseases.